Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Emend; Belgium: Emend; Bulgaria: Emend; Cyprus: Emend; Czech Republic: Emend; Denmark: Emend; Estonia: Emend; Finland: Emend; France: Emend; Germany: Emend; Greece: Emend; Hungary: Emend; Ireland: Emend; Italy: Emend; Latvia: Emend; Lithuania: Emend; Luxembourg: Emend; Malta: Emend; Netherlands: Emend; Poland: Emend; Portugal: Emend; Romania: Emend; Slovakia: Emend; Slovenia: Emend; Spain: Emend; Sweden: Emend; UK: Emend.

North America

Canada: Emend; USA: Emend.

Latin America

Argentina: Emend.

Drug combinations


Aprepitant: C~23~H~21~F~7~N~4~O~3~. Mw: 534.43. (1) 3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-; (2) 3-[[(2R,3S)-3-(p-Fluorophenyl)-2-[[(αR)-α-methyl-3,5-bis(trifluoromethyl)benzyl]oxy]morpholino]methyl]-Δ^2^-1,2,4-triazolin-5-one. CAS-170729-80-3 (2000).

Pharmacologic Category

Antiemetics, Miscellaneous; Substance P/Neurokinin-1 Receptor Antagonist. (ATC-Code: A04AD12).

Mechanism of action

Inhibits the substance P/neurokinin-1 (NK~1~) receptor. Augments the antiemetic activity of the 5-HT~3~ receptor antagonist and corticosteroid activity and inhibits both acute and delayed phases of chemotherapy-induced emesis.

Therapeutic use

Prevention of acute and delayed nausea and vomiting associated with emetogenic chemotherapy. Prevention of postoperative nausea and vomiting.

Pregnancy and lactiation implications

Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use only if clearly needed. Not recommended for use during lactation.

Unlabeled use


Hypersensitivity to aprepitant or any component of the formulation. Use with cisapride or pimozide.

Warnings and precautions

Use with caution in hepatic impairment. Not for treatment of existing nausea and vomiting or for chronic continuous therapy. Potential for CYP-mediated interactions exists.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart